Dry eye syndrome
ICD-10 H04.1 · ICD-11 9A79

Dry Eye Syndrome: Next-Line Management After Anti-Inflammatory Therapy Has Not Achieved Adequate Symptom Control

In moderate-to-severe dry eye disease, anti-inflammatory agents form a key part of initial management. When this line of treatment does not achieve the expected reduction in signs and symptoms, a further escalation of care is indicated.

Previous Treatment — Goals Not Reached

Prior therapy: An anti-inflammatory agent — either a short-term ophthalmic corticosteroid or long-term cyclosporine ophthalmic emulsion.

Goals not achieved: Adequate decrease in dry eye signs and symptoms — including reduced itching and blurred vision — with full effect expected within four to eight weeks of treatment.

Next-Line Approach (Partial Summary)

When anti-inflammatory therapy has not provided sufficient relief, the next step involves interventions that target tear drainage and retention, as well as — in severe disease — a biologically derived ocular preparation aimed at supporting the ocular surface. The goal is improvement of patient symptoms, including reduced eye pain.

The full protocol, including specific interventions and regimen details, is available via the structured resource below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.4140/TCP.n.2016.96

View source ↗